In vitro diagnostic (IVD) kits have been widely applied in disease diagnosis, prognosis, and therapeutic monitoring. With rich and vast experience in antibody development, Creative Biolabs has launched a whole series of biomarker-specific IVD antibody development services. Here, we focus on FGFR-3 as a marker of ovarian cancer and chronic myeloid leukemia.
The Overview of FGFR-3
The fibroblast growth factor (FGF) signaling pathway plays an important role in the tissue homeostasis and injury-induced angiogenesis. Aberrant activation of the FGF signaling pathway is linked to genetic disease and cancer. The interactions of FGF receptors (FGFRs) with 18 signaling FGF ligands regulate cell proliferation, differentiation, shape, and movement. FGFR-3, abbreviated for fibroblast growth factor receptor 3, is a protein which is encoded by the FGFR3 gene. It is expressed in cartilage, brain, intestine, and kidneys. The FGFR3 protein is a transmembrane protein. A full length of the FGFR3 protein is composed of an extracellular region. Furthermore, this region is composed of three immunoglobulin-like domains. The extracellular part of the FGFR3 is essential. It interacts with the fibroblast growth factors, which ultimately influences cell mitogenesis and differentiation. Moreover, fibroblast growth factor plays an important role in bone development and maintenance.
Figure 1 Locations of mutated FGFR-3. (Jay Y Cho., 2004)
FGFR-3 Marker of Myeloma
Typically, in human, activating mutations of FGFR3 lead to a variety of forms of dwarfism when the mutations arise within the germ line. Importantly, some of the same activating mutations of FGFR3 known to induce dwarfism have been reported to be related to the IgH translocations of multiple myeloma (MM). A earlier research has also exhibited that overexpression of FGFR3 in the bone marrow of mice resulted in the development of tumors, and antibody-based targeting of FGFR3 in vitro has been shown to be cytotoxic in MM cells with the t(4;14) translocation. These data support the contribution of aberrant FGFR3-expression translocation in the disease pathology of t(4;14) MM. Thus, FGFR3 could be a useful IVD marker and therapeutic target for myeloma.
IVD antibodies are extensively used in immunodiagnostic kits for disease screening, prognosis, and therapeutic monitoring. Through our role as a leading antibody service provider, Creative Biolabs is well-positioned to develop novel FGFR-3-specific antibodies for diagnostic uses. With our versatile IVD platform, we also offer immunoassay development services from scratch to commercial IVD kits. We can start with antigen sequences or available antibody pairs.
For more detailed information, please feel free to contact us or directly send us an inquiry.
Reference
For Research Use Only.
